Saturday 17 October 2026 Export LFWD’s income statement to Excel — free account

Lifeward Ltd.

Lifeward Ltd.’s revenue for fiscal 2025 (year ended December 2025) was $22.0 million, down 14.1% from fiscal 2024. In the quarter to June 2026, revenue grew 15.7%, EPS grew 40.8% and free cash flow fell 52.8%, each against the same quarter a year earlier.

6.00 0.06 −0.99%

Follow LFWD

Alert me

Market cap: $17.2M
P/E: 0.0×
Fwd P/E: −1.4×
Dividend yield: —
F-score: 4/9
Altman Z: −18.75
Beneish M: −3.19
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 45.66%

Capital & Financial Ratios $m

Market Cap 17.17

Revenue 21.82

Net Income (30.83)

Free Cash Flow (17.10)

Net Debt (0.94)

Current Ratio 2.33

Debt/Equity 0.70

P/E ratio 0.00

Fwd P/E (1.35)

P/S ratio 0.77

P/B ratio 1.37

Past 5Y EPS Growth —

This Y EPS Growth 56.92%

Next Y EPS Growth 76.32%

Next Y revenue growth 14.55%

Next 5Y EPS Growth 65.57%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 15.59%

10-year low 10-year high

P/B against its own 10 years 60.70%

10-year low 10-year high

EV/Sales against its own 10 years 30.74%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2017	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	28	7	2	9
Receivables	3	6	6	8
Inventory	6	7	6	6
Other	—	—	—	1
	39	21	16	26

	2023	2024	2025	Q'26
Payables	5	5	6	6
ST’ Debt	—	—	3	—
Other	2	2	1	2
	12	10	12	11

Compound Annual Growth %

	10y	5y	3y
Sales	19.39%	38.06%	58.72%
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	(8.71%)	(17.33%)	(50.22%)

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	4	7	—	—	—
’25	5	6	6	5	22
’24	5	7	6	8	26
’23	1	1	4	7	14
’22	1	2	1	2	6
’21	1	1	2	1	6
’20	1	2	1	1	4

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(4)	(6)	—	—	—
’25	(5)	(4)	(4)	(4)	(17)
’24	(8)	(6)	(4)	(4)	(22)
’23	(5)	(4)	(7)	(4)	(21)
’22	(6)	(4)	(5)	(4)	(18)
’21	(3)	(3)	(3)	(3)	(11)
’20	(4)	(3)	(3)	(2)	(13)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(4)	(6)	—	—	—
’25	(5)	(4)	(4)	(4)	(17)
’24	(8)	(6)	(4)	(4)	(22)
’23	(5)	(4)	(7)	(5)	(21)
’22	(6)	(4)	(5)	(4)	(18)
’21	(3)	(3)	(3)	(3)	(12)
’20	(4)	(3)	(3)	(2)	(13)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(6.70)	(4.12)	—	—	—
’25	(5.52)	(6.96)	(2.40)	(3.60)	(17.16)
’24	(8.76)	(6.00)	(4.20)	(20.77)	(39.98)
’23	(5.88)	(6.72)	(10.92)	(7.91)	(31.08)
’22	(5.88)	(5.88)	(7.56)	(7.56)	(26.04)
’21	(6.72)	(5.88)	(5.04)	(5.04)	(22.68)
’20	(31.08)	(18.48)	(15.12)	(11.76)	(68.89)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	5,355.00	2,205.00	338.10	155.40	34.44	97.44	58.80	47.04	16.92	6.01	Analyst estimates 2026–2028 Powerpack
	High	33,201.00	7,560.00	2,835.00	846.72	227.64	504.00	110.88	74.76	109.20	48.00
People
People	Employees	94	65	58	50	49	51	56	108	80	81
	Revenue/emp, $m	0.06	0.12	0.11	0.10	0.09	0.12	0.10	0.13	0.32	0.27
Income, $m
Income, $m	Revenue	6	8	7	5	4	6	6	14	26	22
	Gross margin, %	12.54	40.00	43.16	55.94	49.83	48.66	34.57	32.14	32.01	38.25
	EBT	(32)	(25)	(22)	(16)	(13)	(13)	(19)	(22)	(29)	(20)
	EBT margin, %	(553.76)	(317.27)	(331.25)	(318.98)	(294.22)	(211.90)	(346.62)	(159.85)	(112.61)	(90.63)
	Net income	(33)	(25)	(22)	(16)	(13)	(13)	(20)	(22)	(29)	(20)
	Depreciation	1	1	0	0	0	0	0	2	4	0
Per share, $
Per share, $	Revenue	931.59	807.60	374.00	71.04	23.40	10.46	7.42	19.50	35.43	18.98
	Earnings	(5,187.52)	(2,562.26)	(1,239.12)	(226.82)	(68.89)	(22.68)	(26.04)	(31.08)	(39.98)	(17.16)
	Cash flow	(4,370.95)	(2,339.79)	(844.23)	(215.96)	(67.07)	(20.10)	(24.10)	(29.08)	(29.98)	(14.49)
	Capex	(69.37)	(2.19)	(0.74)	(0.32)	(0.39)	(0.08)	(0.03)	(0.11)	0.00	(0.01)
	Free cash flow	(4,440.32)	(2,341.98)	(844.97)	(216.28)	(67.46)	(20.18)	(24.13)	(29.20)	(29.98)	(14.51)
	Book value	1,311.11	386.15	111.14	157.14	116.00	156.65	91.80	65.45	26.02	7.24
	Shares, m	0	0	0	0	0	1	1	1	1	1
Valuation, ×
Valuation, ×	P/E	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	P/S	6.76	2.93	0.98	2.55	4.74	9.88	8.54	3.83	0.59	0.36
	P/B	4.81	6.12	3.29	1.15	0.96	0.66	0.69	1.14	0.80	0.96
	EV/Sales	5.80	3.03	0.85	0.65	0.47	(4.75)	(3.61)	1.96	0.40	0.42
	EV/FCF	(1.22)	(1.04)	(0.37)	(0.21)	(0.16)	2.46	1.11	(1.31)	(0.47)	(0.55)
Cash, $m
Cash, $m	Operating cash flow	(28)	(22)	(15)	(15)	(13)	(11)	(18)	(21)	(22)	(17)
	Capex	0	0	0	0	0	0	0	0	—	0
	Free cash flow	(28)	(22)	(15)	(15)	(13)	(12)	(18)	(21)	(22)	(17)
Balance, $m
Balance, $m	Working capital	17	11	8	11	21	88	68	27	11	4
	Total debt	18	15	9	7	1	1	1	—	—	3
	Net debt	(6)	1	(1)	(9)	(20)	(88)	(67)	(28)	(7)	0
	Shareholders’ equity	8	4	2	11	22	89	68	47	19	8
Returns, %
Returns, %	ROA	(113.38)	(90.50)	(114.61)	(79.07)	(49.49)	(20.74)	(23.16)	(32.21)	(61.79)	(74.60)
	ROIC	(733.16)	(305.99)	(1,105.78)	(588.47)	(360.00)	(468.84)	(1,433.22)	(80.09)	(154.06)	(139.70)
	ROE	(222.78)	(413.09)	(766.99)	(244.42)	(79.72)	(22.92)	(24.84)	(38.60)	(88.56)	(146.12)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
ARAY Accuray Incorporated	$20.8M	— (loss-making)	— (loss-making)	−20.87% (below 0%: shrinking)	n/m	+117.83% (above 0%: growing)	35.22%	5.47%	Compare
MODD Modular Medical, Inc.	$20.5M	— (loss-making)	—	—	n/m	−5.61% (below 0%: shrinking)	0.00%	0.00%	Compare
PAVM PAVmed Inc.	$19.4M	— (loss-making)	— (loss-making)	+450.00% (above 0%: growing)	n/m	−125.63% (below 0%: shrinking)	(269.70%)	(21,278.79%)	Compare
BDMD Baird Medical Investment Holdings Limited	$19.2M	— (loss-making)	—	—	n/m	−598.12% (below 0%: shrinking)	—	—	Compare
LFWD Lifeward Ltd.	$17.2M	— (loss-making)	— (loss-making)	+15.71% (above 0%: growing)	n/m	−52.77% (below 0%: shrinking)	40.90%	(62.69%)
ALUR Allurion Technologies, Inc.	$16.7M	— (loss-making)	— (loss-making)	−47.19% (below 0%: shrinking)	n/m	+65.98% (above 0%: growing)	41.70%	(126.60%)	Compare
HSCS HeartSciences Inc.	$15.4M	— (loss-making)	— (loss-making)	−46.15% (below 0%: shrinking)	n/m	+18.18% (above 0%: growing)	61.90%	(139,957.14%)	Compare
IRIX IRIDEX Corporation	$14.5M	— (loss-making)	— (loss-making)	−7.41% (below 0%: shrinking)	n/m	+130.24% (above 0%: growing)	34.19%	(8.19%)	Compare
RBOT Vicarious Surgical Inc.	$14.3M	— (loss-making)	—	—	n/m	+47.33% (above 0%: growing)	0.00%	0.00%	Compare
Median of peers	$18.0M	—	—	−20.87%	—	+32.76%	34.19%	(8.19%)

All 149 Medical Devices stocks →

Lifeward Ltd. (LFWD) key facts

Concern: Lifeward Ltd.’s revenue for fiscal 2025 (year ended December 2025) was $22.0 million, down 14.1% from fiscal 2024.
Lifeward Ltd. (LFWD) is a Medical Devices company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, LFWD traded at $6.00, a market capitalization of $17.2 million.
Return on equity was −146.1% and debt-to-equity 0.70.
Its Piotroski F-score is 4 out of 9 and its Altman Z-score is −18.75 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.